Kura Oncology (KURA)
(Delayed Data from NSDQ)
$18.97 USD
-0.15 (-0.78%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $18.95 -0.02 (-0.11%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 181 - 200 ( 263 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Look to Sky for a Nice View of a KOMET at ASH; Increasing PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Initial Menin Program Data at ASH; Tipifarnib Combo Planned
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Focus Is the Name of the Game for Kura
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Impressive Median Overall Survival for Tipifarnib in HRAS-HNSCC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
When You''re Better Than Prior Therapies, That Says Something
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; AIM Re-Aimed; KO-539 Development Prioritized
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Strategic Focus for Optimized Resource Use Makes Sense to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: May 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Continuing to Build a Strong Precision Targeted Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Tipifarnib HNSCC Study On Track with Fast Track
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Fast Track and Increasing Visibility on AIM-HN as We Near First End-Game
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Looks Like Tipifarnib Ready for Prime Time in AITL
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J